vs
Side-by-side financial comparison of Shutterstock, Inc. (SSTK) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $220.2M, roughly 1.3× Shutterstock, Inc.). Bio-Techne runs the higher net margin — 12.8% vs -7.3%, a 20.1% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-6.4% vs -12.0%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 1.4%).
Shutterstock, Inc. is an American provider of stock photography, stock footage, stock music, and editing tools; it is headquartered in New York. Founded in 2002 by programmer and photographer Jon Oringer, Shutterstock maintains a library of around 200 million royalty-free stock photos, vector graphics, and illustrations, with around 10 million video clips and music tracks available for licensing. Originally a subscription site only, Shutterstock expanded beyond subscriptions into à la carte p...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
SSTK vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $220.2M | $295.9M |
| Net Profit | $-16.0M | $38.0M |
| Gross Margin | 55.8% | 64.6% |
| Operating Margin | -1.1% | 18.4% |
| Net Margin | -7.3% | 12.8% |
| Revenue YoY | -12.0% | -6.4% |
| Net Profit YoY | -1021.0% | 68.3% |
| EPS (diluted) | $-0.47 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $220.2M | $295.9M | ||
| Q3 25 | $260.1M | — | ||
| Q2 25 | $267.0M | $317.0M | ||
| Q1 25 | $242.6M | $316.2M | ||
| Q4 24 | $250.3M | $297.0M | ||
| Q3 24 | $250.6M | $289.5M | ||
| Q2 24 | $220.1M | $306.1M | ||
| Q1 24 | $214.3M | $303.4M |
| Q4 25 | $-16.0M | $38.0M | ||
| Q3 25 | $13.4M | — | ||
| Q2 25 | $29.4M | $-17.7M | ||
| Q1 25 | $18.7M | $22.6M | ||
| Q4 24 | $-1.4M | $34.9M | ||
| Q3 24 | $17.6M | $33.6M | ||
| Q2 24 | $3.6M | $40.6M | ||
| Q1 24 | $16.1M | $49.1M |
| Q4 25 | 55.8% | 64.6% | ||
| Q3 25 | 60.6% | — | ||
| Q2 25 | 60.3% | 62.7% | ||
| Q1 25 | 58.4% | 67.9% | ||
| Q4 24 | 55.1% | 65.3% | ||
| Q3 24 | 58.3% | 63.2% | ||
| Q2 24 | 58.5% | 66.4% | ||
| Q1 24 | 58.8% | 67.4% |
| Q4 25 | -1.1% | 18.4% | ||
| Q3 25 | 12.5% | — | ||
| Q2 25 | 13.0% | -7.5% | ||
| Q1 25 | 4.2% | 12.2% | ||
| Q4 24 | 5.3% | 16.0% | ||
| Q3 24 | 7.2% | 13.8% | ||
| Q2 24 | 9.4% | 15.0% | ||
| Q1 24 | 7.8% | 22.1% |
| Q4 25 | -7.3% | 12.8% | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | 11.0% | -5.6% | ||
| Q1 25 | 7.7% | 7.1% | ||
| Q4 24 | -0.6% | 11.7% | ||
| Q3 24 | 7.0% | 11.6% | ||
| Q2 24 | 1.6% | 13.3% | ||
| Q1 24 | 7.5% | 16.2% |
| Q4 25 | $-0.47 | $0.24 | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.82 | $-0.11 | ||
| Q1 25 | $0.53 | $0.14 | ||
| Q4 24 | $-0.04 | $0.22 | ||
| Q3 24 | $0.50 | $0.21 | ||
| Q2 24 | $0.10 | $0.26 | ||
| Q1 24 | $0.45 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $178.2M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $581.0M | $2.0B |
| Total Assets | $1.4B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $178.2M | $172.9M | ||
| Q3 25 | $165.5M | — | ||
| Q2 25 | $116.4M | $162.2M | ||
| Q1 25 | $112.2M | $140.7M | ||
| Q4 24 | $111.3M | $177.5M | ||
| Q3 24 | $131.4M | $187.5M | ||
| Q2 24 | $74.9M | $152.9M | ||
| Q1 24 | $71.8M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $581.0M | $2.0B | ||
| Q3 25 | $594.4M | — | ||
| Q2 25 | $586.2M | $1.9B | ||
| Q1 25 | $547.2M | $2.0B | ||
| Q4 24 | $518.4M | $2.1B | ||
| Q3 24 | $522.9M | $2.1B | ||
| Q2 24 | $520.4M | $2.1B | ||
| Q1 24 | $541.3M | $2.0B |
| Q4 25 | $1.4B | $2.5B | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $1.3B | $2.7B | ||
| Q3 24 | $1.3B | $2.7B | ||
| Q2 24 | $1.0B | $2.7B | ||
| Q1 24 | $1.0B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $36.2M | — |
| Free Cash FlowOCF − Capex | $25.9M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 4.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $123.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.2M | — | ||
| Q3 25 | $78.4M | — | ||
| Q2 25 | $26.8M | $98.2M | ||
| Q1 25 | $25.2M | $41.1M | ||
| Q4 24 | $8.0M | $84.3M | ||
| Q3 24 | $-11.6M | $63.9M | ||
| Q2 24 | $28.0M | $75.5M | ||
| Q1 24 | $8.3M | $81.0M |
| Q4 25 | $25.9M | — | ||
| Q3 25 | $68.0M | — | ||
| Q2 25 | $15.5M | $93.3M | ||
| Q1 25 | $14.4M | $31.0M | ||
| Q4 24 | $-952.0K | $77.5M | ||
| Q3 24 | $-26.3M | $54.7M | ||
| Q2 24 | $18.9M | $57.5M | ||
| Q1 24 | $-6.2M | $64.5M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 26.1% | — | ||
| Q2 25 | 5.8% | 29.4% | ||
| Q1 25 | 6.0% | 9.8% | ||
| Q4 24 | -0.4% | 26.1% | ||
| Q3 24 | -10.5% | 18.9% | ||
| Q2 24 | 8.6% | 18.8% | ||
| Q1 24 | -2.9% | 21.3% |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 4.2% | 1.5% | ||
| Q1 25 | 4.5% | 3.2% | ||
| Q4 24 | 3.6% | 2.3% | ||
| Q3 24 | 5.9% | 3.2% | ||
| Q2 24 | 4.1% | 5.9% | ||
| Q1 24 | 6.7% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | 5.86× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 1.35× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | -0.66× | 1.90× | ||
| Q2 24 | 7.71× | 1.86× | ||
| Q1 24 | 0.51× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSTK
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
